# Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children

> **NCT01431170** · PHASE1 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 24 (actual)

## Conditions studied

- Congenital Nasolacrimal Duct Obstruction

## Interventions

- **DRUG:** Besivance Treatment Group
- **DRUG:** Polytrim Treatment Group

## Key facts

- **NCT ID:** NCT01431170
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431170, "Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01431170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*